Today's Rundown Spark's CMO set to leave as post-Roche takeover exits continue Sage rethinks SAGE-217 program after phase 3 failure Nouscom interim CEO becomes full-time as Amal exec becomes CMO Eloxx cuts staff, CEO and shakes up leadership team ‘An incredibly stubborn challenge:’ Board diversity in U.K. life sciences companies How targeting tumor blood vessels may help overcome treatment resistance in glioblastoma Twist Bioscience secures $140M plus a slew of new DNA partnerships Trump taps VP Pence to lead U.S. coronavirus response Featured Story | | | Thursday, February 27, 2020 Spark Therapeutics’ chief medical officer Kathy Reape is set to leave the biotech. Reape is one of the senior Spark staffers hitting the exit in the aftermath of Roche’s $4.3 billion takeover. |
|
|---|
|
| | Download a recent study highlighting the root of key challenges clinical operations professionals are struggling with to complete their oversight responsibilities and the important solutions this study reveals. Read Now >> |
Top Stories Thursday, February 27, 2020 Sage Therapeutics has suspended enrollment in two clinical trials of its depression drug in response to the failure of a phase 3 study. The action is intended to give Sage time to talk to the FDA and weigh potential amendments to the two paused phase 3 trials. Thursday, February 27, 2020 Nouscom has finally got its permanent CEO as it also nabs a new chief medical officer out of Amal Therapeutics. Thursday, February 27, 2020 As Eloxx looks to posts full data from its midstage cystic fibrosis test in the coming months, it has swung the ax on its staffers and hired a new chief executive. Thursday, February 27, 2020 At first glance, British companies are boosting their board diversity. Since 2011, the 100 largest companies trading on the London Stock Exchange have increased the percentage of women on their boards from 12.5% to 33%—and they have done so without government-mandated quotas for board representation. But has the life sciences sector kept pace? Wednesday, February 26, 2020 Widely used VEGF inhibitors that block tumor blood vessel growth have so far failed to rein in brain cancer. Scientists at the University of Pennsylvania showed in mice that targeting the mechanism that gives endothelial cells their ability to act like stem cells might help overcome drug resistance in glioblastoma. Wednesday, February 26, 2020 Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten public offering. Wednesday, February 26, 2020 As the case count for the novel coronavirus multiplies in countries around the world, U.S. officials wants to keep a lid on the outbreak in America. On Wednesday, President Donald Trump tapped Vice President Mike Pence to lead the United States' response. Resources Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Molecular Med TRI-CON: Final Days to Register! March 1-4, 2020 | Moscone North Convention Center | San Francisco, CA BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA Drug Discovery Chemistry – Choose from 45 Presentations from Top Pharma April 13-17, 2020 | San Diego, CA BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA 2nd Annual World Pharma Week: Driving Innovation in Drug R&D June 2-4, 2020 | Boston, MA BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 